Defining and treating high-risk multiple myeloma

Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, discusses the use of gene expression profiling (GEP) to define high-risk multiple myeloma (HRMM). Prof. van Rhee explains how there is still a significant unmet need in this patient population, despite improvements in treatment regimens, and concludes by discussing the need to conduct clinical trials to evaluate the efficacy of bispecific antibodies and CAR-T cells in these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.